Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PHILIP EDWARD LAMMERS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1780802330
CMS profile
80658
Location
BARTLETT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$17,879.72

112 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $13,934.50 5
Food and Beverage $2,093.12 102
Honoraria $1,100.00 2
Travel and Lodging $752.10 3

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–112 of 112 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PHILIP EDWARD LAMMERS

NPI 1780802330 · CMS profile ID 80658

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BARTLETT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–112 of 112 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780802330?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PHILIP EDWARD LAMMERS, NPI 1780802330, CMS profile ID 80658. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–112 of 112 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780802330?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). PHILIP EDWARD LAMMERS, NPI 1780802330, CMS profile ID 80658. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–112 of 112 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780802330?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
PHILIP EDWARD LAMMERS, NPI 1780802330, CMS profile ID 80658, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–112 of 112 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1780802330?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

112 matching records · $17,879.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 112 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–112 of 112.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EISAI INC. $12.2304/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908075079 CMS
PFIZER INC. $18.4704/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949110365 CMS
Celgene Corporation $13.7604/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932697821 CMS
Celgene Corporation $17.2904/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932697819 CMS
Daiichi Sankyo Inc. $550.0004/12/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930858831 CMS
Janssen Biotech, Inc. $13.9604/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886566615 CMS
Coherus Biosciences Inc. $17.2504/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956563575 CMS
Novartis Pharmaceuticals Corporation $19.4404/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893871383 CMS
Pharmacyclics LLC, an AbbVie Company $12.6704/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890342861 CMS
Seagen Inc. $22.9104/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904120641 CMS
Daiichi Sankyo Inc. $1,370.0001/27/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930888297 CMS
Daiichi Sankyo Inc. $342.5001/27/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930888377 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,562.71 70
PY2020 $5,329.83 22
PY2021 $5,379.29 5
PY2022 $17,879.72 112
PY2023 $9,636.16 125
PY2024 $49,174.19 195
PY2025 $65,938.69 193

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,334.64 1
PY2025 Principal investigator $690,641.69 59
PY2024 Principal investigator $1,125,319.16 50
PY2023 Principal investigator $313,910.92 49
PY2022 Recipient $2,376.00 1
PY2022 Principal investigator $176,173.23 32
PY2021 Principal investigator $62,871.40 11
PY2020 Principal investigator $111,504.07 8
PY2019 Principal investigator $6,648.00 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $68,062.68 12/31/2025 Non-covered Recipient Entity
Baptist Cancer Center
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received No dispute reported 06/30/2026 1232924418
Principal investigator 1 Janssen Research & Development, LLC $561.00 12/25/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After Osimertinib Failure No dispute reported 06/30/2026 1175369778
Principal investigator 1 Aveo Pharmaceuticals, Inc. $10,653.36 12/24/2025 Non-covered Recipient Entity
Baptist Clinical Research Institute Inc
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912129
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746256
Principal investigator 1 Iovance Biotherapeutics, Inc. $998.00 11/06/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
117145 No dispute reported 06/30/2026 1252498695
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746254
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,724.00 10/23/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737175
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,250.00 10/23/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737177
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $117.00 10/23/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737179
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 10/23/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737181
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746252
Principal investigator 1 Janssen Research & Development, LLC $500.00 09/29/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175369868
Principal investigator 1 Boehringer Ingelheim International GmbH $509.10 09/24/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746236
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 09/24/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746238
Principal investigator 1 Boehringer Ingelheim International GmbH $539.46 09/24/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746240
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 09/24/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746242
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 09/24/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746244
Principal investigator 1 Boehringer Ingelheim International GmbH $5.68 09/24/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746246
Principal investigator 1 Boehringer Ingelheim International GmbH $143.00 09/24/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746248
Principal investigator 1 Boehringer Ingelheim International GmbH $30.66 09/24/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746250
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 09/12/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746234
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 09/09/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
117145 No dispute reported 06/30/2026 1252497931
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Baptist Trinity Home Care And Hospice-Memphis
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220746232
Principal investigator 1 Iovance Biotherapeutics, Inc. $282.40 08/14/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
101623 No dispute reported 06/30/2026 1252497699
Principal investigator 1 Janssen Research & Development, LLC $4,920.00 08/11/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175369861
Principal investigator 1 AstraZeneca UK Limited $12,070.00 07/23/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
a multicentre,open label study assessing ophthalmic safety of camizestrant in ER,HER2 early breast cancer patients either initiating adjuvant endocrine based therapy cambria 2 or having been treated with standard adjuvant endocrine based therapy for at least 2 years cambria 1 No dispute reported 06/30/2026 1185541742
Principal investigator 1 Genentech, Inc. $2,034.90 07/18/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INST INC
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211576958
Principal investigator 1 Janssen Research & Development, LLC $5,790.00 07/10/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175369873
Principal investigator 1 Genentech, Inc. $13,500.00 07/02/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INST INC
Early Stage to Locally Advanced Non Small Cell Lung Cancer platform stage 3 unresectable No dispute reported 06/30/2026 1211576940
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,368.42 06/24/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
117145 No dispute reported 06/30/2026 1252496049
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,996.00 06/24/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
117145 No dispute reported 06/30/2026 1252496279
Principal investigator 1 Iovance Biotherapeutics, Inc. $13,234.32 06/24/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
117145 No dispute reported 06/30/2026 1252496281
Principal investigator 1 Amgen Inc. $158,554.51 06/17/2025 Non-covered Recipient Entity
BAPTIST CANCER CENTER MEMPHIS THORACIC
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) No dispute reported 06/30/2026 1246639517
Principal investigator 1 Genentech, Inc. $3,500.00 06/13/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INST INC
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211576946
Principal investigator 1 Janssen Research & Development, LLC $5,944.00 06/09/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175369829
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,330.04 06/04/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185541730
Principal investigator 1 Amgen Inc. $174,207.17 05/22/2025 Non-covered Recipient Entity
BAPTIST CANCER CENTER MEMPHIS THORACIC
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) No dispute reported 06/30/2026 1246639519
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,682.80 05/13/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
117145 No dispute reported 06/30/2026 1252496275
Principal investigator 1 Iovance Biotherapeutics, Inc. $66.00 05/13/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
117145 No dispute reported 06/30/2026 1252496277
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,090.40 04/24/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
101623 No dispute reported 06/30/2026 1252495883
Principal investigator 1 Janssen Research & Development, LLC $12,500.00 04/16/2025 Non-covered Recipient Entity
Bapt Clinic Rsrch Inst
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175273129
Principal investigator 1 Genentech, Inc. $7,947.90 04/04/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INST INC
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211576950
Principal investigator 1 AstraZeneca Pharmaceuticals LP $250.00 04/02/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 1185541736
Principal investigator 1 Genentech, Inc. $8,597.00 04/01/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INST INC
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211576954
Principal investigator 1 Janssen Research & Development, LLC $2,972.00 03/31/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175369811
Principal investigator 1 AstraZeneca UK Limited $27,324.90 03/19/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185541740
Principal investigator 1 AstraZeneca UK Limited $10,156.04 03/10/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) No dispute reported 06/30/2026 1185541738
Principal investigator 1 Janssen Research & Development, LLC $2,972.00 02/28/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175369822
Principal investigator 1 Janssen Research & Development, LLC $32,000.00 02/24/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175369882
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,206.66 02/19/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185541734
Principal investigator 1 Iovance Biotherapeutics, Inc. $693.90 02/18/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
117145 No dispute reported 06/30/2026 1252496315
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,955.20 02/11/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
101623 No dispute reported 06/30/2026 1252496337
Principal investigator 1 Janssen Research & Development, LLC $8,916.00 02/03/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175369771
Recipient Amgen Inc. $2,334.64 02/01/2025 Covered Recipient Physician Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer No dispute reported 06/30/2026 1246637188
Principal investigator 1 Amgen Inc. $18,954.40 01/29/2025 Non-covered Recipient Entity
BAPTIST CANCER CENTER MEMPHIS THORACIC
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy No dispute reported 06/30/2026 1246639523
Principal investigator 1 Amgen Inc. $29,340.59 01/27/2025 Non-covered Recipient Entity
BAPTIST CANCER CENTER MEMPHIS THORACIC
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) No dispute reported 06/30/2026 1246639521
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,050.00 01/24/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185541732
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $98.00 01/17/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE INC
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737173
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 01/02/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
117145 No dispute reported 06/30/2026 1252496547
Principal investigator 1 Iovance Biotherapeutics, Inc. $600.00 01/02/2025 Non-covered Recipient Entity
BAPTIST CLINICAL RESEARCH INSTITUTE
117145 No dispute reported 06/30/2026 1252496549